Aurinia Pharmaceuticals Inc. (AUPH)
Chart Events
Performance Outlook
| Previous Close | 10.99 |
| Open | 11.19 |
| Bid | 11.44 x 800 |
| Ask | 11.45 x 800 |
| Day's Range | 10.93 - 11.51 |
| 52 Week Range | 8.86 - 33.97 |
| Volume | |
| Avg. Volume | 2,983,443 |
| Market Cap | 1.485B |
| Beta (5Y Monthly) | 1.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.22 |
| Earnings Date | Feb 22, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.83 |
- Business Wire
Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress
VICTORIA, British Columbia, May 16, 2022--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced that data from multiple studies of LUPKYNIS™ (voclosporin) will be presented at the 59th European Renal Association (ERA) Congress and at the European Congress of Rheumatology, European Alliance of Associations for Rheumatology (EULAR) 2022. The 2022 ERA Congres
- Zacks
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of -3.85% and 9.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Aurinia Reports First Quarter 2022 Financial and Operational Results
VICTORIA, British Columbia, May 10, 2022--AURINIA REPORTS FIRST QUARTER 2022 FINANCIAL AND OPERATIONAL RESULTS
